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Abstract
Purpose To investigate the role of patient-specific dosimetry
as a predictive marker of survival and as a potential tool for
individualised molecular radiotherapy treatment planning of
bone metastases from castration-resistant prostate cancer, and
to assess whether higher administered levels of activity are
associated with a survival benefit.
Methods Clinical data from 57 patients who received 2.5–
5.1 GBq of 186Re-HEDP as part of NIH-funded phase I/II
clinical trials were analysed. Whole-body and SPECT-based
absorbed doses to the whole body and bone lesions were cal-
culated for 22 patients receiving 5 GBq. The patient mean
absorbed dose was defined as the mean of all bone lesion-
absorbed doses in any given patient. Kaplan–Meier curves,
log-rank tests, Cox’s proportional hazards model and
Pearson’s correlation coefficients were used for overall surviv-
al (OS) and correlation analyses.
Results A statistically significantly longer OS was associated
with administered activities above 3.5 GBq in the 57 patients
(20.1 vs 7.1 months, hazard ratio: 0.39, 95 % CI: 0.10–0.58,
P = 0.002). A total of 379 bone lesions were identified in 22
patients. The mean of the patient mean absorbed dose was 19
(±6) Gy and the mean of the whole-body absorbed dose was
0.33 (±0.11) Gy for the 22 patients. The patient mean
absorbed dose (r = 0.65, P = 0.001) and the whole-body
absorbed dose (r = 0.63, P = 0.002) showed a positive corre-
lation with disease volume. Significant differences in OS were
observed for the univariate group analyses according to
disease volume as measured from SPECT imaging of 186Re-
HEDP (P = 0.03) and patient mean absorbed dose
(P = 0.01), whilst only the disease volume remained signifi-
cant in a multivariable analysis (P = 0.004).
Conclusion This study demonstrated that higher administered
activities led to prolonged survival and that for a fixed admin-
istered activity, the whole-body and patient mean absorbed
doses correlated with the extent of disease, which, in turn,
correlated with survival. This study shows the importance of
patient stratification to establish absorbed dose–response
correlations and indicates the potential to individualise
treatment of bone metastases with radiopharmaceuticals
according to patient-specific imaging and dosimetry.
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Introduction
Prostate cancer is the second most common cancer in men,
with an estimated 1.1 million new cases worldwide in 2012
[1]. As the disease progresses to the castration-resistant stage,
more than 80 % of patients develop bone metastases, which
results in poor quality of life with an increase in skeletal pain
and complications such as pathological fractures and spinal
cord compression [2]. Systemic molecular radiotherapy with
bone-seeking agents including 32P, 89Sr-chloride, 153Sm-
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EDTMP, 186Re-HEDP and 188Re-HEDP has beenwidely used
in the management of pain [3].
The use of radiopharmaceuticals in cancer metastatic to
bone is rapidly increasing. 223Ra-dichloride has been
shown to improve survival compared to placebo [4] and
radiolabelled anti-prostate-specific membrane antigen
(PSMA)-targeted therapies show promise for diagnostic
and therapeutic management of CRPC [5]; although long-
term outcome data are not yet available for these agents.
Repeated treatments and combination with chemotherapy
and/or external beam radiotherapy have also demonstrated
improved pain control [6–14]. Currently, most treatments
are based on fixed levels of administered activity, which
has resulted in a wide range of absorbed dose delivered to
patients treated with bone-seeking radiopharmaceuticals
[15–19]. A similar approach to that routinely used in
external beam radiotherapy, whereby radiation doses
delivered to tumours are safely maximised, would, in many
cases, entail higher activity administrations, given the low
levels of toxicity reported. This study investigated such
potential for personalised treatments. To our knowledge,
this is the largest study of bone lesion dosimetry to date.
Although 186Re-HEDP is seldom used at present, the
long-term follow-up data, methodology and results present
valuable information for the design of future trials with
bone-seeking radiopharmaceuticals.
186Re is a beta emitter with a half-life of 3.72 days,
maximum beta energy of 1.07 MeV, average particle
ranges of 1.1 mm in soft-tissue and 0.5 mm in bone, and
a 9 % gamma ray emission at 137 keV that can be used for
imaging. Chelated to hydroxyethylidene-diphosphonate
(HEDP), 186Re-HEDP binds to hydroxyapatite crystals in
bone and within 24 h approximately 70 % is excreted via
the urine [20]. Several studies have examined the safety
and efficacy of 186Re-HEDP in castration-resistant pros-
tate cancer (CRPC) from administered activities ranging
from 1110 to 3515 MBq. Average pain response rates
from 50 to 89.5 %, and durations of pain relief for
6–10 weeks have been observed [21–34]. Toxicity was
limited to mild transient myelosupression, with the platelet
and white blood cell count nadir at 4 weeks [35] and a
maximum tolerated activity of 2960 MBq was established
[36].
To test the hypothesis that absorbed doses can be used
as a predictive biomarker for outcome, a post-hoc analysis
was performed using data from phase I and II clinical
trials aimed at bone pain palliation in patients with meta-
static CRPC treated with high levels of 186Re-HEDP and
autologous peripheral stem cell transplantation. The im-
pact of administered levels of activity and absorbed doses
delivered on overall survival (OS) was assessed. A sec-
ondary aim was to investigate whether the absorbed dose
delivered is associated with the extent of disease in order
to study how this could determine the levels of adminis-
tered activity.
Materials and methods
Patient population
Data are presented from phase I activity escalation and phase
II fixed activity clinical trials conducted to examine the feasi-
bility and safety profile of high administered activity levels of
186Re-HEDP and autologous peripheral blood stem cell trans-
plantation for bone pain palliation in patients with metastatic
CRPC [37, 38]. The patient cohort comprised 57 patients.
Image data were obtained for 22 patients administered
5 GBq to allow dosimetry calculations. Eligibility criteria
and population characteristics were the same in both trials
and have been presented previously [37, 38]. A summary of
patient characteristics relevant to the survival analysis are pre-
sented in Tables 1 and 2, including baseline prostate-specific
antigen (PSA), alkaline phosphatase (ALP), haemoglobin,
albumin and creatinine levels, administered activity and bone
score/disease volume. The use of other therapies subsequent
to 186Re-HEDP which have been proven to prolong survival
such as docetaxel or 223Ra-dichloride is also indicated. All
patients provided written informed consent to take part in
the trials, which were approved by the Royal Marsden NHS
Foundation Trust and The Institute of Cancer Research Ethics
committee.
Data acquisition
Whole-body retention measurements were obtained using
a 5-cm-diameter by 5-cm-thick collimated sodium iodide
(NaI) scintillation detector 2 m above the patient [39].
Acquisition times were chosen to ensure Poisson noise
levels were below 6 %. Anterior and posterior readings
were measured within the limitations of catheterisation,
which sometimes prevented measurements in the prone
position. Up to 10 retention measurements were acquired
over the 4 days following administration. To quantify the
activity levels, the first measurement was obtained imme-
diately after administration, before any activity was excret-
ed from the patient.
Single-photon emission computed tomography (SPECT)
scans of the thorax and pelvis were acquired at approximately
1, 4, 24, 48 and 72 h after administration using a Forte dual-
head gamma camera (Philips Medical Systems, Reigate, UK)
with a low-energy, high-resolution collimator. Patients were
scanned with their arms down and the SPECT images
comprised 64 projections (20 s per projection) per head in
128 × 128 matrices with a 4.67-mm voxel size. Energy
windows with widths of 20 and 7 % were centred on the main
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186Re peak at 137 keVand for scatter correction just below the
peak at 119 keV, respectively. CT scans were not available.
SPECT data were reconstructed using filtered-back projection
(FBP) and pre-filtered with a Butterworth filter of order 2 and
cut-off 1. Images were scatter-corrected using the dual-energy
window method (DEW) and attenuated-corrected using a uni-
form linear attenuation coefficient of 0.142 cm−1 within ellip-
tical patient outlines. Awhole-body scan acquired with a scan
speed of 12 cm/min, 1–2 days following administration, con-
firmed that the majority of lesions were seenwithin the field of
view of the pelvic and thoracic SPECT scans.
Dosimetry
To compensate for the underestimation of the activity in the
bone lesions due to partial volume effects, a recovery curve
was obtained using 11 cylindrical phantoms (1 × 1, 1.5 × 1.5,
2 × 2, 3 × 3, 4 × 4, 5 × 5, 1 × 10, 2 × 10, 3 × 10, 4 × 10 and
5 × 10 cm). Volumes ranged from 0.8 to 196 ml and contained
186Re with an average activity concentration of 2.20 (±0.05)
MBq/ml. Each of the cylinders was placed in a large water-
filled cylinder of 19 cm diameter and 11 cm height, scanned,
and reconstructed using the same parameters as for the patient
data. Optimum threshold values to recover the physical phan-
tom volumes were obtained.
Whole-body absorbed doses were calculated from the re-
tention data with corrections applied for individual patient
mass. Activity quantification for imaged lesions was achieved
by volume of interest analysis carried out on a HERMES
workstation (Hermes Medical Solutions, Stockholm,
Sweden) using thresholds and sensitivity factors obtained
from phantom studies. Absorbed dose distributions were ob-
tained from the convolution of a voxelised cumulated activity
distribution and a voxel S-value kernel for 186Re with 4.67-
mm voxels in a soft-tissue density medium. Cumulated activ-
ity distributions were derived from the integration of time-
activity curves obtained from the co-registered sequential
SPECT scans on a voxel by voxel basis. For the uptake phase,
it was assumed that the activity at the time of administration
was zero and linearly increased to the first scan time. For the
last phase, exponential decay with a physical half-life was
assumed from the last scan point to infinity to avoid any bias
introduced by registration errors and redistribution of uptake
at the voxel level. Trapezoidal integration or mono-
exponential fitting were used for the intermediate phases de-
pending whether the activity increased or decreased over time,
Table 1 Baseline characteristics
for patients grouped according to
outcome-oriented cut-point of the
administered activity of 3.5 GBq
Characteristic A <3.5 GBq (n = 12) A >3.5 GBq (n = 45)
PSA (ng/ml) a 76 (29–201) 81 (23–232)
ALP (U/l) a 182 (137–538) 131 (88–275)
LDH (U/l) a* 721 (615–944) 497 (412–595)
Haemoglobin (g/dl) a** 11.4 (10.5–12.4) 12.9 (11.8–13.7)
Albumin (g/l) a 39 (37–39) 38 (35–40)
Administered activity/no. (GBq) a 3.1 (2.7–3.3) 5.0 (4.9–5.0)
Bone scan score b 2 (1–3) 2 (1–3)
Docetaxel or 223Ra use following 186Re-HEDP/no. patients (%) 0 (0) 5 (11)
No.patients lost to follow-up (%) 0 (0) 2 (4)
a Median and interquartile range. b Normal scan; 1: <6 metastases; 2: ≥6, <20 metastases; 3: >20 metastases but
not superscan; 4: superscan or 75 % involvement of the skeleton. * P = 0.01. ** P = 0.009
Table 2 Baseline characteristics for patients grouped according to data-oriented cut-points of the patient mean (PMAD) and whole-body (WBD)
absorbed doses
Characteristic a PMAD <19 Gy (n = 11) PMAD >19 Gy (n = 11) P value WBD <0.28 Gy (n = 11) WBD >0.28 Gy (n = 11) P value
PSA (ng/ml) 28 (21–137) 122 (22–422) 0.3 28 (21–137) 122 (25–422) 0.2
ALP (U/l) 104 (72–127) 193 (98–439) 0.02 104 (72–127) 193 (98–336) 0.06
LDH (U/l) 506 (420–571) 512 (413–766) 0.3 506 (412–520) 564 (434–766) 0.09
Haemoglobin (g/dl) 12.8 (11.7–13.7) 12.9 (11.0–13.3) 0.6 13.1 (12.8–13.7) 11.7 (10.9–13.3) 0.1
Albumin (g/l) 36 (33–39) 35 (33–40) 0.7 37 (35–39) 34 (32–40) 0.3
Disease volume (ml) 81 (25 – 226) 280 (228–364) 0.002 81 (36–226) 299 (229–364) 0.0004
WBD (Gy) 0.25 (0.23–0.28) 0.37 (0.27–0.48) 0.01 0.25 (0.23–0.26) 0.38 (0.33–0.49) 0.0001
PMAD (Gy) 15 (10–17) 23 (22–25) <0.0001 15 (11–19) 22 (18–25) 0.01
a Median and interquartile range
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respectively. The absorbed dose kernel was generated using an
in-house application developed using the EGS++ class library
within the general purpose EGSnrc Monte Carlo (MC) code
[40, 41], which was previously validated [42]. The 186Re de-
cay spectra used in the simulations was obtained from the
RADTABS software [43].
Metastatic bone lesions were outlined on the absorbed dose
distributions on the HERMES workstation using volume-
dependent thresholds obtained from the phantom studies.
The mean absorbed dose delivered was calculated for each
metastatic lesion. For any given patient, the patient mean
absorbed dose was defined as the mean of the individual le-
sion absorbed doses and the disease volume was defined as
the sum of all the lesion volumes identified. The relationships
between the disease volume and the whole-body and patient
mean absorbed doses were investigated. The relationship be-
tween the disease volume and baseline levels of ALP was also
studied.
Response
Baseline and follow-up bone scans were not available to as-
sess treatment response. Following intravenous administration
of 186Re-HEDP, biochemical measurements that included
PSA and ALP were performed weekly before and after treat-
ment until progression. Correlations between the patient mean
absorbed dose and maximum change in PSA and ALP levels
were investigated, where the maximum change was calculated
as the difference between baseline and nadir relative to base-
line level.
Survival
Survival was determined from the date of 186Re HEDP admin-
istration until death from any cause, until the last follow-up or
until the start of treatment with docetaxel or 223Ra-dichloride.
The impact of the administered activity on OS was studied in
the cohort of 57 patients. The sub-cohort of 22 patients, for
whom dosimetry was performed, was used to analyse the im-
pact of the patient mean and whole-body absorbed doses,
volume of disease, and baseline levels of ALP and PSA on
the OS.
Statistical analysis
Mean (± standard deviation) and confidence intervals (CI)
were used to describe normally distributed continuous vari-
ables and the median with range otherwise. Regression anal-
ysis and Pearson’s correlation coefficient were used to assess
linear relationships between two variables. The disease vol-
ume and ALP levels were not normally distributed and, there-
fore, a natural logarithm transformation was applied for the
regression analysis. Differences in PSA and ALP response
were analysed by patient subgroups that included the patient
mean absorbed dose. Statistical significance was assessed
using Fisher’s exact test to compare the proportion of patients
with declines ≥50 % in PSA and ALP levels for mean
absorbed doses below and above the median. Differences be-
tween baseline characteristics were evaluated by the t test or
Mann–Whitney test.
Survival curves were estimated by the Kaplan–Meier meth-
od and comparisons between groups were made with the log-
rank test and hazard ratios (HR) with 95 % CI. The phase I
study showed a statistically significant correlation between
PSA response (≥50 % decrease for ≥4 weeks) and activity
administered (P = 0.015, two-sided Fisher’s test), with a re-
sponse rate of 20 % in patients that received more than
3.5 GBq of 186Re-HEDP [38]. This outcome-oriented cut-
point for the administered activity level was used to divide
the entire patient cohort into two groups to assess the impact
of administered activity on OS. Survival was also studied in
the 22-patient sub-cohort stratified according to dichotomised
values of the disease volume, the patient mean absorbed dose,
the whole-body absorbed dose, and baseline levels of ALP
and PSA. A data-oriented cut-point based on median values
was chosen for these variables as a biologically driven ap-
proachwas not available and this provided equal sized groups.
The effect of disease volume, and whole-body and patient
mean absorbed doses on OS was also assessed by using mul-
tivariable Cox regression analysis. Two-sided exact P values
below 0.05 were considered statistically significant.
Results
Dosimetry
A 40 % threshold recovered volumes down to 10 ml and
thresholds of 58 and 71 % were necessary to recover the
1.5 × 1.5 and 1 × 1 cm cylinders, respectively. A total of 379
metastatic lesions were identified in 22 patients that received
an administered activity of 5 GBq of 186Re-HEDP, with a
median of 11 lesions (range: 2–60) and 227 ml of disease
volume (range: 17–913 ml) per patient (Fig. 1a). The mean
whole-body absorbed dose was 0.33 (±0.11) Gy (95 % CI:
0.28–0.38 Gy). Individual lesion absorbed doses ranged from
4 to 78 Gy (Fig. 1b). The patient mean absorbed dose ranged
from 8 to 31 Gy with a mean of 19 (±6) Gy (95 % CI: 16–
22 Gy) across the 22 patients. Median values of the whole-
body and patient mean absorbed doses across all patients of
0.28 and 19 Gy, respectively, were used for the grouped sur-
vival analysis.
The patient mean absorbed dose (r = 0.65, P = 0.001) and
the whole-body absorbed dose (r = 0.63, P = 0.002) showed
positive correlations with the disease volume, shown in
Fig. 2a and b.
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Response
The maximum change in PSA and ALP levels for each patient
was grouped according to the patient mean absorbed dose,
shown in Fig. 3. A total of 8 out of 22 patients had a decrease
≥50 % in ALP and 7 out of 22 patients had a decrease ≥50 %
in PSA levels. However, the reduction of PSA (P = 1.0) and
ALP (P = 1.0) levels were not related to the patient mean
absorbed dose.
Survival
Two patients were lost to follow-up and, therefore, censored at
the last point of contact. Five patients were censored at the
time of treatment with docetaxel or 223Ra-dichloride to avoid
bias due the survival benefit associated with these therapies.
The median OS from the time of treatment was 17.5 months
for the entire patient cohort, with estimated 1- and 2-year
survival rates of 72 % (95 % CI: 58–82 %) and 31 % (95 %
CI: 19–43%), respectively. The median OS for the sub-cohort
of 22 patients was 18.5 months.
Kaplan–Meier curves and HR for the univariable grouped
analyses are shown in Fig. 4. The grouped analysis of the 57
patients showed that administered activities above 3.5 GBq
were associated with a 61 % death risk reduction (HR, 0.39;
95 % CI, 0.10–0.58; P = 0.002), with a median OS of
20.1 months as compared to 7.1 months in the lower activity
group. Table 1 shows statistically significant differences in
baseline levels of lactate dehydrogenase (LDH) and
haemoglobin. However, according to Halabi’s nomogram
[44], these differences in prognostic factors cannot explain
the 13 months of survival benefit observed.
In the sub-cohort (Fig 4b to f), median OS of 16.5 and
30.1 months was observed in patients receiving patient mean
absorbed doses above and below 19 Gy (HR, 3.1; 95 % CI,
1.4–9.9; P = 0.01), and of 15.9 and 20.4 months for patients
receiving whole-body absorbed doses above and below
0.28 Gy (HR, 2.4; 95 % CI, 0.9–6.4; P = 0.07), respectively.
A longer OS (22.0 vs 15.9 months) was observed in patients
with a smaller disease volume (HR, 2.8; 95 % CI, 1.1–8.0;
P = 0.03). Median OS values of 21.3 and 18.3 months were
obtained for baseline ALP levels below and above 121 U/l
(HR, 2.6; 95 % CI, 1.1–7.5; P = 0.04), and 21.7 and
16.5 months for baseline PSA levels below and above
78 ng/ml (HR, 2.8; 95% CI, 1.5–12.0; P = 0.02), respectively.
The Cox regression analysis including the disease volume
(HR, 5.7; 95 % CI, 1.7–18.4; P = 0.004), whole-body
absorbed dose (HR, 0.003; 95 % CI, 0.0–2.0; P = 0.08) and
patient mean absorbed doses (HR, 1.0; 95 % CI, 0.9–1.1;
P = 0.9); showed that only the disease volume retained its
significance in predicting OS. Differences in baseline charac-
teristics between groups divided according to patient mean
and whole-body absorbed doses (Table 2) were significant
for ALP levels and disease volume, in addition to the expected
cut-point variables. This was expected as the absorbed doses
are correlated with the disease volume (Fig. 2a and b), which,
in turn, was positively correlated with ALP levels (r = 0.65,
P = 0.001; Fig. 2c).
Discussion
This post-hoc analysis found a significantly longer OS asso-
ciated with administered activities above 3.5 GBq and showed
Fig. 1 Box plot representing the
intra- and inter-patient variability
of the lesion volumes (a) and
absorbed doses (b) for the sub-
cohort of 22 patients. For any
given patient, the whiskers
display the minimum and
maximum values. The patient
mean absorbed dose and mean
lesion volume are shown with full
diamond symbols
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that patients with a higher disease volume received higher
whole-body and patient mean absorbed doses.
A total of 379 lesions were identified in 22 patients. Inter-
patient comparisons showed a range of absorbed doses deliv-
ered from fixed administered activities with a mean patient
mean absorbed dose of 19 (±6) Gy across the 22 patients, in
agreement with a former feasibility study [45]. A large hetero-
geneity in the absorbed dose delivered to individual lesions
was observed, ranging from 4 to 78 Gy for administrations of
5 GBq. These are in close agreement with those calculated by
Israel et al. [46] using quantitative sequential SPECT imaging,
with lesion absorbed doses ranging from 0.36 to 8.03 Gy from
administered activities of 1380–1850 MBq. Maxon et al.
reported a significantly higher lesion mean absorbed dose of
40 Gy from 1.225 GBq, although these calculations were not
based on SPECT imaging [22]. Whole-body absorbed doses
of 0.04–0.12 mGy/MBq from 5 GBq and peripheral stem cell
transplantation were obtained in this study, which are compa-
rable to 0.03–0.18 mGy/MBq from 1.251 to 4.144 GBq re-
ported by Graham et al. [47].
Accurate calculation of the absorbed doses delivered
to bone lesions is challenging. Uptake of bone-seeking
radiopharmaceuticals does not directly reflect the tumour
volume, as it depends on the osteoblastic activity. The
spatial resolution of available clinical systems does not
allow the heterogeneous distribution of uptake at the
microscopic level to be determined. Therefore, it was
assumed that the uptake was indicative of the extent of
the bone lesion, similar to other studies performing bone
lesion dosimetry [15–19]. More refined dosimetry
calculations would account for differences in the uptake
distribution at the microscopic level. Samaratunga et al.
developed a heterogeneous dosimetry model based
on Monte Carlo radiation transport simulations,
histomorphometry and autoradiography analysis of the
186Re-HEDP deposition in bone lesions [48]. They found
that the uniform uptake model underestimates the
absorbed dose to osteoblastic and mixed lesions by fac-
tors of up to 1.84 and 1.39, respectively, with similar
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results for osteolytic lesions. However, this study was
based on bone biopsies from a single metastatic site and
its use is, therefore, limited. The methodology presented
here is more practical in a routine clinical setting. The
relative absorbed doses obtained for the large number of
lesions identified are not expected to be greatly affected
by the assumptions made. Nonetheless, this highlights the
necessity for standardisation of imaging protocols and
dosimetry methodology to enable the comparison of
treatments. The present availability of multimodality and
hybrid imaging has the potential to provide improved
image quantification and dosimetry. Furthermore, both
therapeutic and diagnostic radiopharmaceuticals that
show comparable mechanisms of uptake may enable
adaptive treatment planning for repeated treatments.
For a fixed level of administered activity, higher whole-
body and patient mean absorbed doses were delivered in pa-
tients with a larger disease volume. Patients with more metas-
tases were expected to receive a higher whole-body absorbed
dose, as a larger proportion of the administered activity is
retained in patients with more lesions. However, it had not
been anticipated that the lesion mean absorbed dose would
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also be higher. Previous studies have shown a positive linear
correlation between the bone uptake as a percent of the ad-
ministered activity and the number of metastatic bone lesions
for 153Sm-EDTMP and 186Re-HEDP due to the lower urinary
excretion in patients with a large disease volume [49, 50] . Our
study found no correlation between the absorbed doses and
the renal function, determined from the glomerular filtration
rate (GFR) measured before treatment using the 51Cr-EDTA
clearance rate. Farhanghi et al. concluded that the wide ranges
in renal excretion could not be attributed to variations in renal
function, since all the patients had normal creatinine levels
[49]. Using 89Sr, Blake et al. found that low values of renal
clearance correlated with the elevation of serum parathyroid
hormone and nephrogenous cyclic adenosine monophosphate
levels, which, in turn, correlated with the disease volume [51].
An increase in bone uptake could also occur in response to an
increase in bone mineral turnover as the disease progresses and
newmetastases develop.All these biomarkers are likely to play
a significant role in the absorbed doses delivered. Further
studies with larger patient cohorts are needed to fully elucidate
the mechanisms of uptake of bone-seeking radiopharmaceuti-
cals and to establish absorbed dose response correlations.
This study has demonstrated that other factors may be use-
ful to predict response to treatment with molecular radiother-
apy. A significantly longer OS was associated with adminis-
tered activities above 3.5 GBq of 186Re-HEDP (7.1 vs
21.2 months, P = 0.002). A similar survival advantage at
higher administered activities has also been reported in pa-
tients treated with anti-PSMA 177Lu-J591, with median OS
of 11.9 and 21.8 months (P = 0.03) for administered activities
of 2.4 and 2.6 GBq, respectively [52]. Our study also found
that a shorter survival was associated with higher absorbed
doses due to the positive correlation between absorbed dose
and the disease volume. The multivariable analysis showed
that patient mean absorbed dose was not correlated with sur-
vival when corrected for the disease volume, which is a well-
established prognostic marker of survival in metastatic pros-
tate cancer [53–55].
From the theragnostic point of view, dosimetry can be in-
dicative of functional aggressiveness of the disease in addition
to being a marker of response, since higher absorbed doses are
associated with a higher probability of cell kill. The results
found in this post-hoc analysis suggest that the administered
activity and the absorbed doses delivered to the whole body
and the bone lesions have potential use as predictive bio-
markers, which warrant further studies. The OS benefit ob-
served for higher administered activities would be limited by
red marrow toxicity. Buffa et al. developed a model to predict
the whole-body dose prior to treatment with 186Re-HEDP
based on individual patient biochemical and physiological
parameters, finding a strong correlation between whole-body
absorbed dose and platelet and white blood cell count toxicity
[56]. Such models could be extended to incorporate
information from bone metastases markers to provide a meth-
od of personalised treatment.
Conclusion
A statistically significant survival benefit was observed for
higher administered activities. The wide range of absorbed
doses delivered from a fixed administered activity was indic-
ative of the heterogeneity of the disease. Similar studies with
other bone-seeking radiopharmaceuticals are required to fully
understand the role of the different biomarkers in the absorbed
doses delivered and to determine whether quantitative imag-
ing and dosimetry can lead to individualised treatment plan-
ning. Given the correlation of disease volume with absorbed
dose, activity escalation trials with patients stratified accord-
ing their skeletal tumour burden could help to identify in more
detail absorbed dose response correlations. The implementa-
tion of imaging and dosimetry will enable the development of
novel methods of sequential administration of radiopharma-
ceuticals and adaptive treatment planning in patients with
CRPC treated with radiopharmaceuticals.
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